KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.82 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 226.15% year-over-year to $0.82, compared with a TTM value of $2.33 through Dec 2025, up 206.88%, and an annual FY2025 reading of $2.33, up 206.88% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.82 for Q4 2025 at Alnylam Pharmaceuticals, down from $2.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.21 in Q3 2025 and bottomed at -$3.32 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.99, with a median of -$1.23 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 354.02% in 2025, while the deepest fall reached 300.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.16 in 2021, then rose by 22.22% to -$1.68 in 2022, then skyrocketed by 36.9% to -$1.06 in 2023, then skyrocketed by 38.68% to -$0.65 in 2024, then skyrocketed by 226.15% to $0.82 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ALNY at $0.82 in Q4 2025, $2.21 in Q3 2025, and -$0.56 in Q2 2025.